文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

宫颈癌外照射放疗中技术、靶区选择、勾画、剂量处方与剂量计划的重要性:从EMBRACE-I到II的实践演变

Importance of Technique, Target Selection, Contouring, Dose Prescription, and Dose-Planning in External Beam Radiation Therapy for Cervical Cancer: Evolution of Practice From EMBRACE-I to II.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-03-21

EMBRACE-I纳入1416例局部晚期宫颈癌患者(2008至2015年),EMBRACE-II初始阶段纳入153例(2016年3月至2018年3月),后者采用详细方案与认证流程。从EMBRACE-I到II初始阶段,盆腔CTV和盆腔加腹主动脉旁淋巴结CTV的中位V43 Gy分别减少972 mL(41%)和1130 mL(39%),中位CI分别从1.54降至1.02和从1.51降至1.03。应用IMRT/VMAT、IGRT和45 Gy剂量可提高适形性并显著减少治疗体积。

要点

  • EMBRACE-II采用IMRT/VMAT、每日IGRT、 elective CTV 45 Gy/25次及病理淋巴结同步整合推量。
  • 盆腔CTV:EMBRACE-I中位PTV 1549 mL、V43 Gy 2390 mL、CI 1.54;EMBRACE-II分别为1388 mL、1418 mL、1.02。
  • 盆腔加腹主动脉旁淋巴结CTV:EMBRACE-I中位PTV 1921 mL、V43 Gy 2895 mL、CI 1.51;EMBRACE-II分别为1720 mL、1765 mL、1.03。

核心结论

  • 应用IMRT/VMAT、IGRT和45 Gy剂量可提供更高适形性,从而显著减少治疗体积。
  • 遵循包括全面认证在内的详细方案(如EMBRACE-II)可大幅降低V43 Gy和V50 Gy,并改善适形性和机构间一致性。

研究设计与样本

  • EMBRACE-I纳入1416例局部晚期宫颈癌患者,于2008至2015年接受放化疗(包括图像引导自适应近距离放疗)。
  • EMBRACE-II正在进行中,自2016年3月至2018年3月纳入153例患者,采用外照射靶区勾画、治疗计划和图像引导的全面详细策略及认证流程。
  • 评估并比较两项研究的外照射计划靶区体积、治疗体积(V43 Gy)和适形指数(CI;V43 Gy/PTV)。

主要发现

  • EMBRACE-I中,60%患者接受适形放疗,40%接受IMRT/VMAT; elective CTV 45至50 Gy/25至30次。
  • EMBRACE-I盆腔CTV(82%)中位PTV 1549 mL、V43 Gy 2390 mL、CI 1.54;盆腔加腹主动脉旁淋巴结CTV(15%)中位PTV 1921 mL、V43 Gy 2895 mL、CI 1.51。
  • EMBRACE-I中,盆腔CTV接受45至46 Gy时,适形放疗相比IMRT/VMAT的中位V43 Gy体积大546 mL。
  • EMBRACE-I中,盆腔CTV采用IMRT时,剂量处方≥48 Gy相比45至46 Gy的中位V43 Gy体积大428 mL。
  • EMBRACE-II中,所有患者接受IMRT/VMAT、每日IGRT、 elective CTV 45 Gy/25次及病理淋巴结同步整合推量;盆腔CTV(61%)中位PTV 1388 mL、V43 Gy 1418 mL、CI 1.02;盆腔加腹主动脉旁淋巴结CTV(32%)中位PTV 1720 mL、V43 Gy 1765 mL、CI 1.03。

关键数值与推荐

  • 从EMBRACE-I到EMBRACE-II初始阶段,盆腔照射的中位V43 Gy减少972 mL(41%),中位CI从1.54降至1.02。
  • 从EMBRACE-I到EMBRACE-II初始阶段,盆腔加腹主动脉旁淋巴结照射的中位V43 Gy减少1130 mL(39%),中位CI从1.51降至1.03。

临床怎么用

  • EMBRACE-II方案采用IMRT/VMAT、每日IGRT、 elective CTV 45 Gy/25次及病理淋巴结同步整合推量。
  • 遵循包括全面认证在内的详细方案可降低V43 Gy和V50 Gy并改善适形性和机构间一致性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe the evolution of external beam radiation therapy (EBRT) from EMBRACE-I (general guidelines for EBRT) to the initial phase of the EMBRACE-II study (detailed protocol for EBRT). METHODS AND MATERIALS: EMBRACE-I enrolled 1416 locally advanced cervical cancer patients treated with chemoradiation including image-guided adaptive brachytherapy during 2008 to 2015. From March 2016 until March 2018, 153 patients were enrolled in the ongoing EMBRACE-II study, which involves a comprehensive detailed strategy and accreditation procedure for EBRT target contouring, treatment planning, and image guidance. EBRT planning target volumes (PTVs), treated volumes (V43 Gy), and conformity index (CI; V43 Gy/PTV) were evaluated in both studies and compared. RESULTS: For EMBRACE-I, conformal radiation therapy (60% of patients) or intensity-modulated radiation therapy (IMRT) and volumetric arc therapy (VMAT; 40%) was applied with 45 to 50 Gy over 25 to 30 fractions to the elective clinical target volume (CTV). For pelvic CTVs (82%), median PTV and V43 Gy volumes were 1549 and 2390 mL, respectively, and CI was 1.54. For pelvic plus paraortic nodal (PAN) CTVs (15%), median PTV and V43 Gy volumes were 1921 and 2895 mL, and CI was 1.51. For pelvic CTVs treated with 45 to 46 Gy, the use of conformal radiation therapy was associated with a median V43 Gy volume that was 546 mL larger than with IMRT/VMAT. For pelvic CTVs treated with IMRT, the use of a dose prescription ≥48 Gy was associated with a median V43 Gy volumes that was 428 mL larger than with a dose prescription of 45 to 46 Gy. For EMBRACE-II, all patients were treated with: IMRT/VMAT, daily IGRT, 45 Gy over 25 fractions for the elective CTV, and simultaneously integrated boost for pathologic lymph nodes. For pelvic CTVs (61%), median PTV and V43 Gy volumes were 1388 and 1418 mL, and CI was 1.02. For pelvic plus PAN CTVs (32%), median PTV and V43 Gy volumes were 1720 and 1765 mL, and CI was 1.03. From EMBRACE-I to initial II, median V43 Gy was decreased by 972 mL (41%) and 1130 mL (39%), and median CI decreased from 1.54 to 1.02 and 1.51 to 1.03 for pelvic and pelvic plus PAN irradiation, respectively. CONCLUSIONS: Application of IMRT/VMAT, IGRT, and a 45-Gy dose provides the potential of higher conformality inducing significant reduction of treated volume. Adherence to a detailed protocol including comprehensive accreditation, as in EMBRACE-II, reduces considerably V43 Gy and V50 Gy and improves conformality and interinstitutional consistency.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Berger T, Seppenwoolde Y, Pötter R, et al. Importance of Technique, Target Selection, Contouring, Dose Prescription, and Dose-Planning in External Beam Radiation Therapy for Cervical Cancer: Evolution of Practice From EMBRACE-I to II. Int J Radiat Oncol Biol Phys. 2019. PMID: 30904706. doi:10.1016/j.ijrobp.2019.03.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。